Posts tagged “Biotech & Life Science”

8:56 a.m. yesterday

Biogen stock spikes on Alzheimer's drug results

Biogen's RTP plant Biogen, which has a major manufacturing facility in Durham, saw its stock spike sharply Thursday after an abstract on results from a Phase I Prime study on its Alzheimer's drug leaked.

1:00 p.m. Wednesday

Premium Lock From A to Z: November a busy month for NC fundraising

Dollar sign      Reviewing SEC filings for November makes clear how busy the month was for North Carolina technology, life science and other emerging companies were in seeking to raise new capital. From A to Z, here's the list.

7:14 a.m. Wednesday

Premium Lock How US can improve our security through nanobiotechnology

Securitization of supply chains, authentication of products, and preventing counterfeiting have challenged businesses for centuries. The problems continue to become more daunting as globalization and transfer of goods and products becomes more complex. The tools and techniques of Nanotechnology and Biotechnology are beginning to provide some answers to these challenges.

6:35 a.m. Wednesday

Emerging RTP biotech company UVision raising $2M

North Carolina Business News Wire UVision, a young North Carolina biotechnology company, has filed to raise $2 million in equity, according to a filing with the Securities and Exchange Commission.

1:55 p.m. Tuesday

Raleigh biotech startup Locus seeks to raise $7M

Locus Biosciences, a Raleigh-based company wants to raise $7 million in a private offering, according to a filing with the Securities and Exchange Commission.

Locus Biosciences Locus Biosciences

Updated 1:50 p.m. Tuesday

Eshelman-backed G1, Genetech to test combo cancer therapy

​G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, will team up with biotech pioneer Genentech on a cancer clinical trial in the new year.

G1 Therapeutics G1 Therapeutics

9:35 a.m. Tuesday

NCSU researchers tweak enzyme 'assembly line' to improve antibiotics

Researchers from North Carolina State University have discovered a way to make pinpoint changes to an enzyme-driven "assembly line" that will enable scientists to improve or change the properties of existing antibiotics as well as create designer compounds.

Enzyme assembly line Enzyme assembly line

8:24 a.m. Tuesday

Chapel Hill's Cempra edges closer to big payoff with Phase 3 drug trial in Japan

Prabhavathi Fernandes, Ph.D., CEO, Cempra Cempra says Toyama Chemical Co., a subsidiary of Fujifilm Holdings Corp., began Phase 3 clinical trials with its pneumonia-fighting drug in Japan, the world's second-largest antibiotic market.

Updated 2:35 p.m. Monday

Premium Lock Metabolon raises another $15M from big life science investor

Essex Woodlands, a $2.5 billion equity investment firm, is taking another $15 million stake in RTP-based Metabolon, which focuses on the growing field of metabolomics.

Metabolon's headquarters Metabolon's headquarters

11:09 a.m. Monday

GSK names new leader for ViiV Healthcare

ViiV Healthcare Dr. Dominique Limet is leaving after seven years as the CEO of GSK-owned ViiV Healthcare, which focuses on treatments for HIV. He will be replaced by GSK executive Deborah Waterhouse.

Updated 9:32 a.m. Monday

December's tech events calendar a busy one + A look to 2017

Social networking The year 2016 will draw to a busy close for Triangle tech firms with a host of events on the calendar. Here's the latest update plus a look at early 2017 and what groups meet where. and when.

5:25 a.m. Monday

58 headlines not to be missed: WTW week in review, part 3

Triangle headlines Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part three.

5:20 a.m. Monday

58 headlines not to be missed: WTW week in review, part 2

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part two.

5:15 a.m. Monday

58 headlines not to be missed: WTW's week in review, part 1

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for this past week, part one.

5:10 a.m. Monday

Speak up: WTW wants to hear from you - Send us news, views

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

December 1

Heat Biologics stock plunges 50% after unfavorable drug trial results

Heat Biologics stock fell more than 50 percent in Thursday morning trading after the drug developer announced that its bladder cancer drug did not produce favorable results in a Phase 2 trial.

Heat Biologics Heat Biologics

Techwire Inside Partners
The Skinny: A Blog by Rick Smith